Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riluzole crossover trial in 22q11.2 deletion syndrome
NL-OMON52172Phase 4Completed
- Sponsor
- Maastricht University Medical Center+
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of riluzole in Velocardiofacial syndrome (VCFS), sponsored by Maastricht University Medical Center+. Primary endpoints: Change in glutamate concentration in the anterior cingulate cortex and Change in GABA concentration in the anterior cingulate cortex. Started Mar 2022; status: completed.
02
Drugs
riluzole
03
Conditions
Velocardiofacial syndrome (VCFS)
Beyond the preview
Go deeper on NL-OMON52172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52172.